A unique approach to control the CD40/CD154 inflammatory axis in type 1 diabetes
A unique approach to control the CD40/CD154 inflammatory axis in type 1 diabetes
批准号:
8716665
负责人:
David H. Wagner
金额:
$23.26万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-07 至 2015-07-31
关键词:
AddressAdipocytesAffectAmino Acid SequenceAmino AcidsAntibodiesAntibody FormationAntigen-Presenting CellsAntigensAutoantigensAutoimmune ProcessAutoimmunityBindingBlood PlateletsCell DeathCell SurvivalCell surfaceCellsClinicalDataDendritic CellsDiabetes MellitusDiagnosisDoseEffector CellEpithelial CellsExperimental Autoimmune EncephalomyelitisGoalsGrantHumanHyperglycemiaImmune responseImmunosuppressionInbred NOD MiceInflammationInflammatoryInsulinInsulin-Dependent Diabetes MellitusInterleukin-6InvadedIslets of LangerhansLigandsModelingMonoclonal AntibodiesMultiple SclerosisMusNatural regenerationPathogenicityPeptide Sequence DeterminationPeptide Signal SequencesPeptidesPlayPopulationRegulatory T-LymphocyteResearchRoleSignal TransductionSiteSystemic Lupus ErythematosusT memory cellT-LymphocyteT-Lymphocyte SubsetsTNFRSF5 geneTNFSF5 geneTherapeuticThrombosisTransplantationTumor Necrosis Factor Receptorbasecrosslinkcytokinedesigndiabetes controldiabeticefficacy testinghigh riskhuman subjectinhibitor/antagonistinnovationisletmacrophagemembermouse modelpreventpublic health relevancereceptorresponsesmall moleculesuccesstrafficking
中文摘要
描述(由申请人提供):CD40/CD154炎症轴已被证明在自身免疫性炎症中起关键作用。人们曾尝试使用抗体和合成有机小分子来控制它;每一种最终都未能成为有效的治疗方法。用抗CD154控制该轴被证明是非常有效的,但是抗体本身在人体试验中造成了致命的问题。我们设计了一个小的(15-mer)治疗肽(STP),它来源于已知与CD40相互作用的CD154氨基酸序列。我们确定STP直接结合到表达CD40的细胞表面,特别是CD40+ T细胞,我们在NOD小鼠T1D模型和人类T1D中描述为高致病性的一个亚群。糖尿病前期人类受试者对胰岛有反应的CD4+CD40+细胞水平升高。仅用这种肽治疗T细胞可减少胰岛反应。与混乱肽或更小的肽相比,在96%的NOD治疗小鼠中,给予肽可以预防高血糖。重要的是,组成肽的氨基酸数量对功效至关重要。在这个应用中,我们将研究这种肽的作用机制。目的1:假设:STP对致病效应T细胞,特别是CD4+CD40+细胞有直接作用:探讨其耐受机制。目的2将探讨多肽如何影响整体免疫反应,包括抗原召回、针对外来抗原的潜在抗体产生以及多肽治疗诱导CD154抗体的可能性。这项研究计划的最终目标是创造一种治疗方法来控制致病效应T细胞。
英文摘要
DESCRIPTION (provided by applicant): The CD40/CD154 inflammatory axis has proven critical in autoimmune inflammation. Attempts to control it have used antibodies and synthesized organic small molecules; each ultimately has failed to be useful as a therapeutic. Controlling that axis with anti- CD154 proved highly effective, but the antibody itself caused lethal problems in human trials. We designed a small (15-mer) therapeutic peptide (STP) derived from the CD154 amino acid sequence that is known to interact with CD40. We determined that the STP binds directly to cell surface expressed CD40, particularly to CD40+ T cells, a subset that we described as highly pathogenic in the NOD mouse model of T1D, and in human T1D. Pre-diabetic human subjects have elevated levels of CD4+CD40+ cells that respond to human islets. Treating only T cells with the peptide ablates islet response. Administration of the peptid prevents hyperglycemia in 96% of treated NOD mice compared to a scrambled peptide or smaller versions of the peptide. Importantly the number of amino acids comprising the peptide is crucial for efficacy. In this application we will examine the mechanism of action of this peptide. Aim 1: Hypothesis: The STP has direct effects on pathogenic effector T cells, specifically CD4+CD40+ cells: Exploring the mechanism(s) of tolerance. Aim 2 will explore how the peptide affects the overall immune response including antigen recall, potential antibody production to foreign antigens and the possibility that peptide treatment induces antibodies to CD154. The ultimate goals of this research plan are to create a therapeutic to control pathogenic effector T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes
-
批准号:10345075
-
项目类别:
-
资助金额:$44.01万
-
财政年份:2022
-
负责人:David H. Wagner
-
依托单位:
Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes
-
批准号:10589075
-
项目类别:
-
资助金额:$44.01万
-
财政年份:2022
-
负责人:David H. Wagner
-
依托单位:
A unique approach to control the CD40/CD154 inflammatory axis in type 1 diabetes
-
批准号:8508619
-
项目类别:
-
资助金额:$18.16万
-
财政年份:2013
-
负责人:David H. Wagner
-
依托单位:
CD40-Induced TCR Revision: A Mechanism for Autoimmunity
-
批准号:8000721
-
项目类别:
-
资助金额:$15.46万
-
财政年份:2010
-
负责人:David H. Wagner
-
依托单位:
CD40-Induced TCR Revision: A Mechanism for Autoimmunity
-
批准号:8113290
-
项目类别:
-
资助金额:$27.29万
-
财政年份:2007
-
负责人:David H. Wagner
-
依托单位:
CD40-Induced TCR Revision: A Mechanism for Autoimmunity
-
批准号:7771490
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2007
-
负责人:David H. Wagner
-
依托单位:
CD40-Induced TCR Revision: A Mechanism for Autoimmunity
-
批准号:7313568
-
项目类别:
-
资助金额:$28.41万
-
财政年份:2007
-
负责人:David H. Wagner
-
依托单位:
CD40-Induced TCR Revision: A Mechanism for Autoimmunity
-
批准号:7655274
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2007
-
负责人:David H. Wagner
-
依托单位:
CD40-Induced TCR Revision: A Mechanism for Autoimmunity
-
批准号:7473258
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2007
-
负责人:David H. Wagner
-
依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
-
批准号:81970721
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:陶凌
-
依托单位: